6.2 Status Epilepticus Emergency Protocols & Algorithm

Status Epilepticus Emergency Protocols & Algorithm

Definition and the Concept of t1/t2 Thresholds

Status Epilepticus (SE) is a life-threatening neurological emergency characterized by prolonged or recurrent seizures without full recovery of consciousness between episodes. The definition of SE has evolved significantly to facilitate earlier and more aggressive intervention. The current Neurocritical Care Society (NCS) and International League Against Epilepsy (ILAE) guidelines operationalize the definition using two critical time points: t1 and t2 thresholds.

The t1 threshold is the time at which a seizure should be regarded as an "abnormally prolonged seizure" and emergency treatment should be initiated. For generalized convulsive status epilepticus (GCSE), the t1 threshold is set at 5 minutes. This is based on robust clinical evidence that typical generalized tonic-clonic seizures spontaneously cease within 2-3 minutes; seizures persisting beyond 5 minutes are unlikely to stop on their own and require pharmacological intervention.

The t2 threshold is the time point at which long-term consequences, such as neuronal injury, alteration of neuronal networks (epileptogenesis), and pharmacoresistance, begin to occur. For GCSE, the t2 threshold is 30 minutes. Therefore, the overarching goal of SE management is to completely terminate clinical and electrographic seizure activity well before the t2 threshold is reached to prevent irreversible neurological damage.

For focal status epilepticus with impaired consciousness (complex partial SE), the timeframes are longer: t1 is 10 minutes, and t2 is >60 minutes. For absence status epilepticus, t1 is 10-15 minutes, and t2 is unknown, though it rarely causes significant neuronal injury.

Pathophysiology of Status Epilepticus

Understanding the pathophysiology of SE is crucial for effective management. As a seizure continues, profound changes occur at the cellular and receptor levels. Within minutes, there is a dramatic internalization (endocytosis) of inhibitory GABA-A receptors from the synaptic membrane into the intracellular space. Concurrently, there is an externalization (exocytosis) of excitatory NMDA and AMPA receptors to the synaptic membrane.

This receptor trafficking results in a state of diminished inhibitory capacity and amplified excitatory drive. Clinically, this manifests as rapidly increasing resistance to GABAergic medications, such as benzodiazepines, as the seizure persists. Furthermore, prolonged seizures cause systemic physiological derangements, including hypoxemia, hypercapnia, hypoglycemia, hyperthermia, lactic acidosis, and massive catecholamine release, which can lead to cardiac arrhythmias, neurogenic pulmonary edema, and rhabdomyolysis.

Emergency Protocols and the Treatment Algorithm

The management of SE follows a structured, time-dependent algorithmic approach divided into distinct phases: Stabilization, Initial Therapy, Second Therapy, and Third Therapy (Refractory SE).

0-5 Minutes: Stabilization Phase

The immediate priority is the ABCs (Airway, Breathing, Circulation).

• Ensure a patent airway and provide supplemental oxygen. Intubation may be necessary if airway reflexes are compromised.
• Establish secure intravenous (IV) access.
• Perform a rapid bedside point-of-care blood glucose check. Hypoglycemia is a rapidly reversible cause of SE. If glucose is <60 mg/dL, administer 100 mg of thiamine IV (to prevent Wernicke's encephalopathy) followed by 50 mL of 50% dextrose (D50) IV.
• Obtain vital signs, perform continuous ECG monitoring, and send blood for STAT laboratory tests (electrolytes, calcium, magnesium, renal and hepatic function, toxicology screen, and AED levels if applicable).

5-20 Minutes: Initial Therapy Phase

The goal in this phase is to rapidly terminate the seizure using first-line medications, which are exclusively benzodiazepines. Intravenous administration is preferred.

• Lorazepam (Ativan): 0.1 mg/kg IV (max 4 mg per dose), administered at a maximum rate of 2 mg/min. This can be repeated once after 5-10 minutes if seizures persist.
• Diazepam (Valium): 0.15 - 0.2 mg/kg IV (max 10 mg per dose), administered at 5 mg/min. Can be repeated once.
• Midazolam (Versed): 10 mg intramuscular (IM) for adults (>40 kg) or 5 mg IM for children (13-40 kg). IM midazolam is the preferred option when IV access is unavailable, as proven by the RAMPART trial, due to its rapid absorption.

20-40 Minutes: Second Therapy Phase

If seizures continue despite adequate doses of benzodiazepines, the patient is in established SE, and second-line AEDs must be administered immediately. The choice of agent should consider patient comorbidities, allergies, and current medications. The three primary options are fosphenytoin, valproic acid, and levetiracetam.

The landmark Established Status Epilepticus Treatment Trial (ESETT), a randomized, double-blind, multicenter trial, compared the efficacy of these three agents in benzodiazepine-refractory SE. The trial demonstrated that fosphenytoin, valproic acid, and levetiracetam are equally effective, each stopping seizures and improving responsiveness in approximately 50% of patients. None of the drugs proved superior to the others.

• Fosphenytoin (Cerebyx): 20 mg PE (phenytoin equivalents)/kg IV, maximum 1500 mg PE. It is a prodrug of phenytoin, allowing for faster infusion rates (up to 150 mg PE/min) with a lower risk of purple glove syndrome and cardiovascular collapse compared to intravenous phenytoin. Continuous ECG and blood pressure monitoring are mandatory during infusion.
• Valproic Acid (Depacon): 40 mg/kg IV, maximum 3000 mg. Administered at up to 10 mg/kg/min. It is highly effective but should be avoided in patients with suspected mitochondrial disorders, severe hepatic impairment, or women of childbearing potential due to teratogenicity.
• Levetiracetam (Keppra): 60 mg/kg IV, maximum 4500 mg. Administered over 15 minutes. It has an excellent safety profile, minimal drug interactions, and lacks cardiovascular or hepatic toxicity, making it a very popular choice in modern practice.

>40 Minutes: Third Therapy Phase (Refractory Status Epilepticus)

Refractory Status Epilepticus (RSE) is defined as clinical or electrographic seizures that continue after adequate doses of an initial benzodiazepine and a second-line AED. RSE carries a high mortality rate and requires admission to a Neurocritical Care Unit (NCCU), intubation, mechanical ventilation, and continuous EEG (cEEG) monitoring.

The goal in RSE is to induce a pharmacological coma to completely suppress brain electrical activity, typically targeting a burst-suppression pattern on cEEG for 24-48 hours. Continuous intravenous anesthetic infusions are used:

• Propofol: Requires careful monitoring for Propofol Infusion Syndrome (PRIS), characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure.
• Midazolam: Continuous infusion; prolonged use can lead to tachyphylaxis and accumulation, especially in renal impairment.
• Pentobarbital/Thiopental: Highly effective but associated with significant complications, including profound hypotension, myocardial depression, and immunosuppression, necessitating vasopressor support.